Foundation Medicine is a molecular information company developing clinical diagnostic tests that facilitate personalized cancer therapies. It provides clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas that provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. The company also offers a molecular information platform that aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers, and drug developers to help advance the science of molecular medicine in cancer.
TypeSubsidiary
Parent CompanyRoche
HQCambridge, MA, US
Founded2010
Websitefoundationmedicine.com
Cybersecurity ratingCMore
Foundation Medicine was founded in 2010 and is headquartered in Cambridge, MA, US
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Foundation Medicine

Cindy Perettie

Cindy Perettie

Chairman Of The Board
Brian Alexander

Brian Alexander

Chief Executive Officer
Konstantin Fiedler

Konstantin Fiedler

Chief Operating Officer
Winifred Lynn Swan

Winifred Lynn Swan

General Counsel and Chief Legal Officer
Priti Hegde

Priti Hegde

Chief Scientific Officer
Andrew Suchoff

Andrew Suchoff

Chief People Officer
Show more

Foundation Medicine Office Locations

Foundation Medicine has offices in Cambridge, Morrisville, San Diego and Penzberg
Cambridge, MA, US (HQ)
150 Second St
Morrisville, NC, US
7010 Kit Creek Rd
San Diego, CA, US
11010 Torreyana Rd
Penzberg, DE
Nonnenwald 2/building 433 d
Show all (4)

Foundation Medicine Financials and Metrics

Summary Metrics

Founding Date

2010

Total Funding

$96.5 m

Investors

In total, Foundation Medicine had raised $96.5 m. Foundation Medicine is a subsidiary of Roche

Foundation Medicine Revenue

Foundation Medicine's revenue was reported to be $152.9 m in FY, 2017
USDFY, 2017

Revenue

152.9m

Cost of goods sold

85.3m

Gross profit

67.6m

Gross profit Margin, %

44%
USDFY, 2017

Cash

71.4m

Accounts Receivable

20.0m

Inventories

13.2m

Current Assets

123.8m
USDFY, 2017

Net Income

(161.5m)

Depreciation and Amortization

18.5m

Inventories

(2.6m)

Accounts Payable

8.4m
USDFY, 2017

Revenue/Employee

285.8k

Debt/Equity

1.9 x

Debt/Assets

0.4 x

Financial Leverage

5.3 x
Show all financial metrics

Foundation Medicine Operating Metrics

Jan, 2021

Biopharma Partners

50

Patient Profiles in Clinico-Genomic Database

55 k

Patients Tested to Date

400 k

Peer-Reviewed Publications

500

Foundation Medicine Acquisitions / Subsidiaries

Company NameDateDeal Size
Lexent BioJune 12, 2020

Foundation Medicine Revenue Breakdown

Embed Graph

Foundation Medicine revenue breakdown by geographic segment: 92.8% from United States and 7.2% from Other

Foundation Medicine Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Foundation Medicine Online and Social Media Presence

Embed Graph

Foundation Medicine Company Culture

  • Overall Culture

    A-

    76/100

  • CEO Rating

    A

    76/100

  • Compensation

    B

    74/100

  • Diversity

    B-

    71/100

Learn more on Comparably

Foundation Medicine News and Updates

Foundation Medicine, Epic collaboration focuses on genomics for precision oncology

The EHR integration can help practices, hospitals and academic medical centers access genomic information more easily in the EHR, for more streamlined clinical decision support.

TwinStrand Biosciences Licenses Duplex Sequencing Technology to Foundation Medicine

SEATTLE, Nov. 18, 2020 /PRNewswire/ -- TwinStrand Biosciences today announced it has entered into a worldwide non-exclusive agreement to sublicense two foundational patent families to Foundation Medicine and its affiliates relating to TwinStrand Duplex Sequencing™ error-correction...

UPDATE 1-Bayer to work with Foundation Medicine on cancer patient screening

* Genetic sequencing test seen as vital to secure market uptake

Global $85.5 Billion Precision Medicine (Diagnostics/Therapeutics) Market to 2025 - Key Players are GE Healthcare; Abbott Lab, Precision Biologics, Foundation Medicine, Illumina and IBM Watson

DUBLIN, Nov. 16, 2018 /PRNewswire/ -- The "Precision Medicine (Diagnostics/Therapeutics) Market Analysis Report By Application (Genetic Tests, Esoteric Tests, Pharmaceuticals, Medical Devices), By End Use, And Segment Forecasts, 2018 - 2025" report has been added to...

UPDATE 2-Roche pays $2.4 bln for rest of cancer expert Foundation Medicine

* Echoes past biotech buy-outs at Flat Iron and Genentech (Adds more on personalised cancer care, analyst comment)

UPDATE 1-Roche to pay $2.4 bln to buy rest of Foundation Medicine

ZURICH, June 19 (Reuters) - Swiss drugmaker Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI), a $2.4 billion transaction that values the U.S. genomic profiling group at $5.3 billion, the partners said on Tuesday.
Show more

Foundation Medicine Blogs

Celebrating Women’s History Month: A Q&A with Foundation Medicine’s CMO, Mia Levy, MD, PhD

This past year, we’ve made several important additions to our strong and diverse Executive Team. As a whole, they are committed to serving patients, oncologists, and researchers, while fostering a wor...

What’s Next With Priti Hegde: How can immuno-oncology innovation transform care for cancer patients?

Transforming early science into reality is the very essence of R&D, and research—particularly groundbreaking research—takes time. But time is something cancer patients do not have. In order to deliver...

Finding Answers, Empowering Action

In The Emperor of All Maladies, Siddhartha Mukherjee’s Pulitzer Prize-winning “biography of cancer,” the author presents a thought experiment involving Atossa, the Persian queen who suffered from what...

How Real-World Clinico-Genomic Data is Delivering New Cancer Insights | Foundation Medicine

Real-world clinico-genomic data is recognized across the healthcare community as a catalyst to spur potentially life-changing advancements in care and has become instrumental in our joint work to impr...

What a Difference a Year Makes: The Evolving Landscape of Pan-Tumor Liquid Biopsy Testing | Foundation Medicine

As FoundationOne®Liquid CDx marks its first anniversary as an FDA-approved liquid biopsy option for cancer patients, I’d like to look back over the past year and explore the progress we’ve made. In ju...

Making Comprehensive Genomic Profiling Indispensable at a Global Level: Progress, Perspectives and What’s Next | Foundation Medicine

I initially became an oncologist because, to me, treating cancer provided the biggest opportunity to make a difference for people. I learned quickly that the most valuable tool in treating this diseas...
Show more

Foundation Medicine Frequently Asked Questions

  • When was Foundation Medicine founded?

    Foundation Medicine was founded in 2010.

  • Who are Foundation Medicine key executives?

    Foundation Medicine's key executives are Cindy Perettie, Brian Alexander and Konstantin Fiedler.

  • How many employees does Foundation Medicine have?

    Foundation Medicine has 1,813 employees.

  • What is Foundation Medicine revenue?

    Latest Foundation Medicine annual revenue is $152.9 m.

  • What is Foundation Medicine revenue per employee?

    Latest Foundation Medicine revenue per employee is $84.3 k.

  • Who are Foundation Medicine competitors?

    Competitors of Foundation Medicine include Biodesix, Flatiron Health and Myriad Genetics.

  • Where is Foundation Medicine headquarters?

    Foundation Medicine headquarters is located at 150 Second St, Cambridge.

  • Where are Foundation Medicine offices?

    Foundation Medicine has offices in Cambridge, Morrisville, San Diego and Penzberg.

  • How many offices does Foundation Medicine have?

    Foundation Medicine has 4 offices.